Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer

Scott Saxman, Patrick Loehrer, Keith Logie, Doyle Stephens, Frank Workman, Daniel Scullin, Lawrence Einhorn, Rafat Ansari

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19% of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4%. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1-5 day intravenous etoposide administration.

Original languageEnglish
Pages (from-to)253-256
Number of pages4
JournalInvestigational New Drugs
Volume9
Issue number3
DOIs
StatePublished - Aug 1991

Fingerprint

Etoposide
Non-Small Cell Lung Carcinoma
Agranulocytosis
Leukopenia
Intravenous Administration

Keywords

  • etoposide
  • lung cancer

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. / Saxman, Scott; Loehrer, Patrick; Logie, Keith; Stephens, Doyle; Workman, Frank; Scullin, Daniel; Einhorn, Lawrence; Ansari, Rafat.

In: Investigational New Drugs, Vol. 9, No. 3, 08.1991, p. 253-256.

Research output: Contribution to journalArticle

Saxman, Scott ; Loehrer, Patrick ; Logie, Keith ; Stephens, Doyle ; Workman, Frank ; Scullin, Daniel ; Einhorn, Lawrence ; Ansari, Rafat. / Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer. In: Investigational New Drugs. 1991 ; Vol. 9, No. 3. pp. 253-256.
@article{0a2806b067884e10919055e1b4bbbf6a,
title = "Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer",
abstract = "Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19{\%} of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4{\%}. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1-5 day intravenous etoposide administration.",
keywords = "etoposide, lung cancer",
author = "Scott Saxman and Patrick Loehrer and Keith Logie and Doyle Stephens and Frank Workman and Daniel Scullin and Lawrence Einhorn and Rafat Ansari",
year = "1991",
month = "8",
doi = "10.1007/BF00176978",
language = "English",
volume = "9",
pages = "253--256",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer

AU - Saxman, Scott

AU - Loehrer, Patrick

AU - Logie, Keith

AU - Stephens, Doyle

AU - Workman, Frank

AU - Scullin, Daniel

AU - Einhorn, Lawrence

AU - Ansari, Rafat

PY - 1991/8

Y1 - 1991/8

N2 - Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19% of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4%. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1-5 day intravenous etoposide administration.

AB - Forty-six previously untreated patients with advanced non-small cell lung cancer (NSCLC) were entered into a Hoosier Oncology Group phase II trial of daily oral etoposide 50 mg/m2/d. The dose limiting toxicity was granulocytopenia. The non-hematologic toxicity was mild, with only 19% of patients developing Grade 3 or 4 leukopenia. Two partial responses of 10 and 16 weeks duration were seen in 43 evaluable patients, for an overall response rate of 4%. We conclude that daily oral etoposide has minimal activity in advanced NSCLC, and does not improve response rates over conventional 1-5 day intravenous etoposide administration.

KW - etoposide

KW - lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0025878119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025878119&partnerID=8YFLogxK

U2 - 10.1007/BF00176978

DO - 10.1007/BF00176978

M3 - Article

VL - 9

SP - 253

EP - 256

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -